AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 36 using EVA spread proxy -22.0%; growth durability 90.6.
Valuation
Valuation institutional score is 92 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
Technicals institutional score is 38 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
This data source has not been supplied for the decision payload.
Signal Summary
Market intelligence remains Mixed. valuation provide support, while fundamentals and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
1.01
Current
0.82
Overvalued
1.17
Undervalued
0.86
5Y Average
0.83
Current
0.69
Overvalued
0.96
Undervalued
0.71
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.7x Undervalued | -24% vs avg | +9.3% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +22.0% | 15.8% | 25.8x Undervalued | -41% vs avg | +20.5% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 48.4x Fair | +10% vs avg | -1.7% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 36.4x Undervalued | -17% vs avg | +11.3% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | -14% vs avg | -15.8% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 40.0x Fair | -9% vs avg | +28.0% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.8x Fair | -10% vs avg | +30.6% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.2x Premium | +107% vs avg | +116.1% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹51 CrMar 2026Latest net profit
₹5.52 CrMar 2026Latest EPS
₹5.31Mar 2026Net margin
17.4%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 38.12 | 37.70 | 37.52 | 38.38 | 40.20 | 39.14 | 41.03 | 43.41 | 44.36 | 44.24 | 44.58 | 34.15 | 50.80 |
| Expenses + | 31.23 | 31.64 | 32.28 | 33.44 | 35.70 | 34.41 | 36.09 | 38.82 | 39.32 | 39.10 | 39.14 | 32.26 | 41.95 |
| Operating Profit | 6.89 | 6.06 | 5.24 | 4.94 | 4.50 | 4.73 | 4.94 | 4.59 | 5.04 | 5.14 | 5.44 | 1.89 | 8.85 |
| OPM % | 18.07% | 16.07% | 13.97% | 12.87% | 11.19% | 12.08% | 12.04% | 10.57% | 11.36% | 11.62% | 12.20% | 5.53% | 17.42% |
| Other Income + | 0.81 | 0.58 | 0.61 | 0.71 | 1.26 | 0.76 | 0.77 | 1.15 | 1.55 | 1.69 | 1.73 | 2.11 | 2.13 |
| Interest | 1.27 | 1.21 | 1.15 | 1.20 | 1.38 | 1.46 | 1.54 | 1.39 | 1.52 | 1.36 | 1.45 | 1.45 | 1.49 |
| Depreciation | 1.86 | 2.11 | 2.16 | 2.16 | 2.14 | 2.09 | 2.16 | 2.14 | 1.94 | 1.99 | 2.02 | 2.09 | 2.06 |
| Profit before tax | 4.57 | 3.32 | 2.54 | 2.29 | 2.24 | 1.94 | 2.01 | 2.21 | 3.13 | 3.48 | 3.70 | 0.46 | 7.43 |
| Tax % | 26.26% | 25.90% | 22.44% | 25.76% | 24.55% | 24.74% | 54.23% | 23.08% | 16.29% | 27.30% | 24.05% | 19.57% | 25.71% |
| Net Profit + | 3.37 | 2.46 | 1.97 | 1.70 | 1.69 | 1.46 | 0.92 | 1.70 | 2.63 | 2.52 | 2.81 | 0.36 | 5.52 |
| EPS in Rs | 3.66 | 2.65 | 2.12 | 1.82 | 1.81 | 1.56 | 0.90 | 1.64 | 2.54 | 2.44 | 2.72 | 0.35 | 5.31 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Board Meeting Intimation for Consider And Approve The Unaudited Consolidated & Standalone Financial Results Of The Company For The Quarter Ended June 30Th, 2026.
Intimation Under Regulation 30(9) Of SEBI (LODR) Regulations, 2015.